Alterity CFO’s Options Buy Signals Optimism Amid Low‑Priced Shares & Early‑Stage Biotech Uncertainty
Alterity Therapeutics CFO’s option buy signals optimism after a plunge to $0.01, hinting at future milestones while the company remains a high‑risk, early‑stage biotech.
4 minutes to read